Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 2, 2003, Pages 191-198

  Shale, M J ^a   Riley, S A ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DELAYED DRUG RELEASE; DEPRESSION; DOSE RESPONSE; DRUG URINE LEVEL; ENTERITIS; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT COMPLIANCE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; URINALYSIS;

ADULT; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 0042128396     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01648.x     Document Type: Article

References (45)

1. Riley SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 1997; 42: 761-3.
2. Misiewicz JJ, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; i: 185-8.
3. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383-9.
4. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomised, placebo controlled trial. Ann Intern Med 1996; 124: 204-21.
5. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 363-8.
6. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid: Asacol) for the prevention of post-operative recurrence in Crohn's disease. Aliment Pharmacol Ther 1994; 8: 35-43.
7. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-83.
8. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology 1994; 107: 117-20.
9. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-53.
10. Van Hees PA, Van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulphasalazine. J Clin Gastroenterol 1982; 4: 333-6.
11. Kane SV, Cohen RD, Aitkens JE, et al. Prevalence of non-adherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33.
12. Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol 2001; 32: 66-8.
13. Kane SV, Hanauer SB. Medication adherence is associated with improved outcomes in patients with quiescent ulcerative colitis (UC) [Abstract]. Gastroenterology 2000; 118: 4900.
14. Haynes RB. Determinants of compliance: the disease and mechanics of treatment. In: Haynes RB, Taylor DT, Sackett DL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press, 1979.
15. Cienchanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function and costs. Arch Intern Med 2000; 160: 3278-85.
16. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984; 100: 258-68.
17. Peck CL, King NJ. Compliance and the doctor-patient relationship. Drugs 1985; 30: 78-84.
18. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-4.
19. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 590-9.
20. Puller T, Birtwell AJ, Wiles PG, et al. Use of a pharmacological indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 1989; 44: 540-5.
21. Fletcher SW, Pappius EM, Harper SJ. Measurement of medication compliance in a clinical setting: comparison of three methods in patients prescribed digoxin. Arch Intern Med 1979; 139: 635-8.
22. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846-57.
23. Stephenson BJ, Rowe BH, Haynes RB, et al. Is this patient taking the treatment as prescribed? J Am Med Assoc 1993; 269: 2779-81.
24. Gilbert JR, Evans CE, Haynes RB, et al. Predicting compliance with a regimen of digoxin therapy in family practice. Can Med Assoc J 1980; 123: 119-22.
25. Pullar T, Peaker S, Martin MFR, et al. The use of a pharmacological indicator to investigate compliance in patients with a poor response to anti-rheumatic therapy. Br J Rheumatol 1988; 27: 381-4.
26. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
27. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; i: 514.
28. Irvine EJ, Zhou Q, Thompson AK, et al. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. Am J Gastroenterol 1996; 91: 1571-8.
29. Thom DH, Ribisl KM, Stewart AL, et al. Further validation and reliability testing of the Trust in Physician Scale. Med Care 1999; 37: 510-7.
30. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
31. Hussain FN, Ajjan RA, Moustafa M, et al. Simple method for the determination of 5-aminosalicylic and N-acetyl-5-amino-salicylic acid in rectal tissue biopsies. J Chromatogr B 1998; 716: 257-66.
32. Husdan H, Rappoport A. Estimation of creatinine by the Jaffe reaction: a comparison of three methods. Clin Chem 1968; 14: 222-38.
33. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
34. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
35. Hilbrands LB, Hoitsma AJ, Keone RA. Medication compliance after renal transplantation. Transplantation 1995; 60: 914-20.
36. Eisen SA, Woodward RS, Miller D, et al. The effect of medication compliance on the control of hypertension. J Gen Intern Med 1987; 2: 298-305.
37. Sackett DL, Snow JC. The magnitude of compliance and non-compliance. In: Haynes RB, Taylor DT, Sackett DL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press, 1979.
38. Aminosalicylates. British National Formulary, London: British Medical Association, September 2001: 47-49.
39. Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001; 15: 53-62.
40. Robertson DAF, Ray J, Diamond I, et al. Personality profile and affective state of patients with inflammatory bowel disease. Gut 1989; 30: 623-6.
41. Andrews H, Barczak P, Allan RN. Psychiatric illness in patients with inflammatory bowel disease. Gut 1987; 28: 1600-4.
42. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 1973; 14: 923-6.
43. Bardazzi G, d'Albasio G, Bonanomi AG, et al. Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis. Ital J Gastroenterol 1994; 26: 334-7.
44. Dickinson RJ, King A, Wright DGD, et al. Is continuous sulphasalazine necessary in the management of patients with ulcerative colitis? Results of a preliminary study. Dis Colon Rectum 1985; 28: 929-30.
45. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between visits. Arch Intern Med 1990; 150: 1509-10.